[1]邵毅.阿柏西普治疗新生血管性年龄相关性黄斑变性——2017欧洲视网膜专家学会共识解读[J].眼科新进展,2018,38(7):601-605.[doi:10.13389/j.cnki.rao.2018.0142]
　SHAO Yi.Aflibercept treatment for neovascular age related macular degeneration—The Interpretation of The Consensus of European Society of Retina Specialists，2017[J].Recent Advances in Ophthalmology,2018,38(7):601-605.[doi:10.13389/j.cnki.rao.2018.0142]
点击复制

阿柏西普治疗新生血管性年龄相关性黄斑变性——2017欧洲视网膜专家学会共识解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年7期
页码:
601-605
栏目:
述评
出版日期:
2018-07-05

文章信息/Info

Title:
Aflibercept treatment for neovascular age related macular degeneration—The Interpretation of The Consensus of European Society of Retina Specialists，2017
作者:
邵毅
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi
Ophthalmology，the First Affiliated Hospital of Nanchang University，Nanchang 330006，Jiangxi Province，China
关键词:
阿柏西普; 新生血管性年龄相关性黄斑变性; 治疗
Keywords:
aflibercept; neovascular age-related macular degeneration; treatment
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0142
文献标志码:
A
摘要:
阿柏西普治疗新生血管性年龄相关性黄斑变性（neovascular age-related macular degeneration，nAMD）效果较好，但大部分眼科医生尚不清楚治疗方式与周期的选择。通常认为阿柏西普治疗nADM应最少持续1 a（48周），并且每8周给药1次（即给药6次），在第1年治疗结束时（实际在进行第11个月的随访时），应考虑两种治疗方案：不延长治疗间隔即维持固定的每8周给药1次，或延长治疗间隔时间，最长可延长至12周。考虑不延长治疗间隔的标准是：持续性黄斑水肿但视力稳定、复发性黄斑水肿、水肿伴视力下降、黄斑出血、脉络膜新生血管形成或任何其他渗出性疾病活动征象，威胁到视力需临床医生提供建议时。对于干性黄斑（即没有黄斑渗出）和视力稳定患者，推荐延长治疗间隔时间。此外，如果视力和（或）解剖结果恶化，治疗间隔时间也可以缩短。对于黄斑无渗液的眼睛，可以考虑不进行治疗监测，完成一整年监测而不需要注射药物的患者可以考虑出院。对在治疗延长期间疾病复发患者和因出院或终止治疗后疾病复发的患者，需恢复固定的每8周给药1次的治疗方式。对于双眼nAMD患者，双眼均需根据实际情况确定治疗时间表。
Abstract:
Aflibercept has a satisfactory effect on aflibercept in the treatment of neovascular age-related macular degeneration （nAMD），but most ophthalmologists do not know the choice of treatment methods and its periods.It is generally believed that aflibercept for nADM should last at least 48 weeks and once administration every 8 weeks （totally 6-time administration）.At the end of the 11th month of the follow-up，two treatment options should be considered：to maintain the fixed method of once administration every 8 weeks without extending the treatment interval and to extend the treatment interval，which can be extended to a maximum of 12 weeks.And the former treatment method has its criteria of persistent macular edema patients with stable visual acuity，and recurrent macular edema patients accompanied by vision loss，macular hemorrhage，the formation of choroid neovascularization and any other exudative disease activity involving vision loss.Prolonged treatment interval is recommended for patients with dry macular （no macular exudation） and stable vision.In addition，if the visual and/or anatomical results deteriorate，the interval of treatments can be also shortened.For macular eyes without exudation，it is not necessary to consider the monitoring treatment，and discharge can be considered for patients with a full-year monitoring treatment and needless agent administration.As for patients with recurrent diseases，the fixed once medication every 8 weeks should be considered.For binocular nAMD patients，the treatment schedule is needed to determine in both eyes according to the actual eye state.

参考文献/References:

［1］　AMOAKU W M K.The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration［J］.Eye,2008,22(6):864-868.
［2］　CHONG V.Ranibizumab for the treatment of wet AMD：a summary of real-world studies［J］.Eye，2016，30（2）：270-286.
［3］　HOLZ F G，TADAYONI R，BEATTY S，BERGER A，CEREDA MG，CORTEZ R，et al.Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration［J］.Br J Ophthalmol，2015，99（2）：220-226.
［4］　MAGUIRE M G，MARTIN D F，YING G S，JAFFE G J，DANIEL E，GRUNWALD J E，et al.Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration：the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2016，123（8）：1751-1761.
［5］　MCKIBBIN M，DEVONPORT H，GALE R，GAVIN M，LOTERY A，MAHMOOD S，et al.Aflibercept in wet AMD beyond the first year of treatment：recommendations by an expert roundtable panel［J］.Eye （Lond），2015，29（Suppl 1）：S1-S11.
［6］　Aflibercept solution for injection for treating wet age-related macular degeneration.Technology appraisal guidance［TA294］［EB/OL］.（2013-07-24）［2017-04-21］.http://www.nice.org.uk/guidance/ ta294.
［7］　Lucentis? （ranibizumab solution for injection） ［summary of product characteristics］.Camberley，UK：Novartis Europharm Ltd；2016［EB/OL］.［2017-04-21］.https：//www.medicines.org.uk/emc/medicine/19409.
［8］　Eylea?（aflibercept solution for injection） ［summary of product characteristics］.Leverkusen，Germany：Bayer AG；2017［EB/OL］.［2017-08-09］.https：//www.medicines.org.uk/emc/medicine/27224.
［9］　GROUP A.A randomized,placebo-controlled,clinical trial of high-dose supplementation with vitamins C and E,beta carotene,and zinc for age-related macular degeneration and vision loss:AREDS report no.8.Arch Ophthalmol［J］.Arch Ophthalmol，2001，119(10):1417-1436.
［10］　SHIELDS C L,SHIELDS J A.The American Society of Retina Specialists 2016 Founders Award Lecture:retinal tumors:understanding clinical features,OCT morphology,and therapy［J］.Article，2017,1(1):10-23.
［11］　ARNOLD J J,CAMPAIN A,BARTHELMES D,SIMPSON J M,GUYMER R H,HUNYOR A P，et al.Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration［J］.Ophthalmology，2015，122(6):1212-1219.
［12］　DECROOS F C，REED D，ADAM M K，SALZ D,GUPTA O P,HO A C,et al.Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration：a prospective clinical trial［J］.Am J Ophthalmol，2017，180：142-150.
［13］　EPSTEIN D，AMRN U.Near vision outcome in patients with age-related macular degeneration treated with aflibercept［J］.Retina，2016,36（9）：1773-1777.
［14］　ESSEX R W，NGUYEN V，WALTON R，ARNOLD J J,MCALLISTER I L,GUYMER R H,et al.Fight Retinal Blindness Study Group.Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration［J］.Ophthalmology，2016,123（11）：2393-2400.
［15］　VAZQUEZ-ALFAGEME C，PATEL P J，HAMILTON R.Efficacy of aflibercept in treatment-nave neovascular age-related macular degeneration：one-year real world outcomes［J］.Invest Ophthalmol Vis Sci，2015，56:4613.
［16］　TALKS J S，LOTERY A J，GHANCHI F，ANDREW J,LOTERY,FRCO,et al.United Kingdom Aflibercept Users Group.First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration［J］.Ophthalmology，2016,123（2）：337-343.
［17］　ALMUHTASEB H，KANAVATI S，RUFAI S R，LOTERY A J.One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration［J］.Eye （Lond）,2017,31（6）：878-883.
［18］　ALMUHTASEB H，RENNIE C，SAHU D，LOTERY A.Aflibercept 2nd year outcomes in nAMD：unicenter data analysis （Capped PRN vs.Treat and Extend）.The 16th European Society of Retina Specialists （EURETINA） Congress［C］.Denmark：Copenhagen，2016.
［19］　ELEFTHERIADOU M，VAZQUEZ-ALFAGEME C，CITU C M，CROSBY-NWAOBI R,SIVAPRASAD S,HYKIN P,et al.Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting［J］.Am J Ophthalmol，2017，174：160-168.
［20］　ALMUHTASEB H，JOHNSTON R L，TALKS J S，LOTERY A J.Second-year visual acuity outcomes of nAMD patients treated with aflibercept：data analysis from the UK Aflibercept Users Group［J］.Eye，2016，30（11）：1582.
［21］　SCHMIDT-ERFURTH U，KAISER P K，KOROBELNIK J F，LOTERY A J.Intravitreal aflibercept injection for neovascular age-related macular degeneration：ninety-six-week results of the VIEW studies［J］.Ophthalmology，2014，121（1）：193-201.
［22］　REZAEI K A，STONE T W.2016 Global Trends in Retina Survey［C］.Chicago，IL：American Society of Retina Specialists,2016.
［23］　KAISER P K，SINGER M，TOLENTINO M，VITTI R,ERICKSON K A,SAROJ N,et al.Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration.VIEW 1 Extension Study［J］.Ophthalmol Retina，2017，1（4）：304-313.
［24］　MOSHFEGHI D M，HARIPRASAD S M，MARX J L，THOMPSON D，SOO Y，GIBSON A，et al.Effect of fluid status at week 12 on visual and anatomic outcomes at week 52 in the VIEW 1 and 2 trials［J］.Ophthalmic Surg Lasers Imaging Retina，2016，47（3）：238-244.
［25］　HEIER J S，BROWN D M，CHONG V，KOROBELNIK J F，KAISER P K，NGUYEN Q D，et al.VIEW 1 and VIEW 2 Study Groups.Intravitreal aflibercept （VEGF trap-eye） in wet age-related macular degeneration［J］.Ophthalmology，2012，119（12）：2537-2548.
［26］　RICHARD G，MONéS J，WOLF S，KOROBELNIK JF，GUYMER R，GOLDSTEIN M，et al.Scheduled versus pro re nata dosing in the VIEW trials［J］.Ophthalmology，2015，122（12）：2497-2503.

相似文献/References:

[1]邹洪强,田洪芹,张艳平,等.阿柏西普治疗眼底血管性疾病的临床研究新进展[J].眼科新进展,2017,37(9):894.[doi:10.13389/j.cnki.rao.2017.0227]
　ZOU Hong-Qiang,TIAN Hong-Qin,ZHANG Yan-Ping,et al.Recent advances in clinical research on aflibercept treating fundus vascular diseases[J].Recent Advances in Ophthalmology,2017,37(7):894.[doi:10.13389/j.cnki.rao.2017.0227]
[2]卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效[J].眼科新进展,2019,39(4):340.[doi:10.13389/j.cnki.rao.2019.0076]
　LU Qian-Yi.Intravitreal aflibercept injection for the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(7):340.[doi:10.13389/j.cnki.rao.2019.0076]
[3]刘志南,管怀进.雷珠单抗和阿柏西普对年龄相关性黄斑变性患者外层视网膜管状结构的影响[J].眼科新进展,2019,39(10):952.[doi:10.13389/j.cnki.rao.2019.0217]
　LIU Zhi-Nan,GUAN Huai-Jin.Effects of ranibizumab and aflibercept on outer retinal tubulation of patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2019,39(7):952.[doi:10.13389/j.cnki.rao.2019.0217]
[4]张国明,田娅.阿柏西普在眼科疾病治疗中的应用[J].眼科新进展,2020,40(1):001.[doi:10.13389/j.cnki.rao.2020.0001]
　ZHANG Guoming,TIAN Ya.Advances in application of Aflibercept for treatment of ocular diseases[J].Recent Advances in Ophthalmology,2020,40(7):001.[doi:10.13389/j.cnki.rao.2020.0001]
[5]张慧,单伟.阿柏西普对碱烧伤大鼠角膜新生血管的抑制作用[J].眼科新进展,2020,40(2):120.[doi:10.13389/j.cnki.rao.2020.0029]
　ZHANG Hui,SHAN Wei.Inhibitory effect of Aflibercept on corneal neovascularization in rats with alkali burns[J].Recent Advances in Ophthalmology,2020,40(7):120.[doi:10.13389/j.cnki.rao.2020.0029]
[6]罗曼,陈晓隆.新生血管性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物治疗进展[J].眼科新进展,2020,40(6):582.[doi:10.13389/j.cnki.rao.2020.0134]
　LUO Man,CHEN Xiaolong.Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs[J].Recent Advances in Ophthalmology,2020,40(7):582.[doi:10.13389/j.cnki.rao.2020.0134]
[7]肖康,梁申芝,万光明,等.玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿的疗效[J].眼科新进展,2020,40(8):744.[doi:10.13389/j.cnki.rao.2020.0169]
　XIAO Kang,LIANG Shenzhi,WAN Guangming,et al.Efficiency of intravitreal aflibercept for the treatment ofrefractory diabetic macular edema[J].Recent Advances in Ophthalmology,2020,40(7):744.[doi:10.13389/j.cnki.rao.2020.0169]
[8]林杜生,周昭涛,黄晓琼,等.反复玻璃体内注射阿柏西普对黄斑水肿患者角膜的影响[J].眼科新进展,2021,41(4):368.[doi:10.13389/j.cnki.rao.2021.0077]
　LIN Dusheng,ZHOU Zhaotao,HUANG Xiaoqiong,et al.Effect of repeated intravitreal aflibercept injections on the cornea in patients with macular edema[J].Recent Advances in Ophthalmology,2021,41(7):368.[doi:10.13389/j.cnki.rao.2021.0077]
[9]孙浩,李姣,毕宏生,等.阿柏西普对葡萄膜黑色素瘤细胞的作用及其机制研究[J].眼科新进展,2022,42(4):284.[doi:10.13389/j.cnki.rao.2022.0057]
　SUN Hao,LI Jiao,BI Hongsheng,et al.Effect and mechanism of aflibercept on uveal melanoma cells[J].Recent Advances in Ophthalmology,2022,42(7):284.[doi:10.13389/j.cnki.rao.2022.0057]
[10]刘春梦,丁珊,刘雪英,等.Ang/Tie信号轴在新生血管性年龄相关性黄斑变性发病及治疗中的作用[J].眼科新进展,2022,42(6):485.[doi:10.13389/j.cnki.rao.2022.0099]
　LIU Chunmeng,DING Shan,LIU Xueying,et al.Role of Ang/Tie signaling axis in the pathogenesis and treatment of neovascular age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(7):485.[doi:10.13389/j.cnki.rao.2022.0099]

更新日期/Last Update: 2018-07-12